| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Defibrillators, Implantable | 171 | 2023 | 329 | 34.280 |
Why?
|
| Cardiac Resynchronization Therapy | 80 | 2023 | 119 | 25.060 |
Why?
|
| Heart Failure | 109 | 2023 | 1180 | 16.770 |
Why?
|
| Electric Countershock | 59 | 2020 | 130 | 12.200 |
Why?
|
| Arrhythmias, Cardiac | 61 | 2022 | 239 | 11.820 |
Why?
|
| Death, Sudden, Cardiac | 47 | 2022 | 141 | 11.450 |
Why?
|
| Electrocardiography | 88 | 2023 | 601 | 10.360 |
Why?
|
| Cardiac Pacing, Artificial | 68 | 2021 | 174 | 9.840 |
Why?
|
| Tachycardia, Ventricular | 54 | 2022 | 153 | 9.020 |
Why?
|
| Receptors, Antigen, B-Cell | 48 | 2021 | 89 | 8.950 |
Why?
|
| Atrial Fibrillation | 48 | 2022 | 249 | 8.100 |
Why?
|
| B-Lymphocytes | 47 | 2021 | 329 | 7.220 |
Why?
|
| Pacemaker, Artificial | 37 | 2022 | 157 | 7.080 |
Why?
|
| Ventricular Dysfunction, Left | 45 | 2021 | 277 | 6.360 |
Why?
|
| Ventricular Fibrillation | 33 | 2020 | 85 | 5.830 |
Why?
|
| Bundle-Branch Block | 26 | 2023 | 50 | 5.680 |
Why?
|
| Ventricular Remodeling | 27 | 2022 | 318 | 5.120 |
Why?
|
| Heart Ventricles | 31 | 2022 | 738 | 4.950 |
Why?
|
| Ventricular Function, Left | 24 | 2022 | 481 | 4.740 |
Why?
|
| Treatment Outcome | 140 | 2023 | 7029 | 4.580 |
Why?
|
| Humans | 471 | 2023 | 68618 | 4.400 |
Why?
|
| Heart Conduction System | 16 | 2021 | 119 | 4.200 |
Why?
|
| Heart Rate | 34 | 2021 | 568 | 4.070 |
Why?
|
| Catheter Ablation | 14 | 2022 | 229 | 4.040 |
Why?
|
| Prospective Studies | 116 | 2022 | 3705 | 3.650 |
Why?
|
| Aged | 187 | 2023 | 14862 | 3.390 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 14 | 2022 | 22 | 3.350 |
Why?
|
| Female | 280 | 2023 | 38074 | 3.270 |
Why?
|
| Middle Aged | 204 | 2022 | 21147 | 3.200 |
Why?
|
| Male | 277 | 2023 | 37321 | 3.190 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 22 | 2020 | 61 | 3.170 |
Why?
|
| Algorithms | 30 | 2020 | 1196 | 2.850 |
Why?
|
| Signal Transduction | 47 | 2021 | 2689 | 2.830 |
Why?
|
| Heart Failure, Systolic | 8 | 2019 | 16 | 2.690 |
Why?
|
| Primary Prevention | 12 | 2020 | 115 | 2.610 |
Why?
|
| Prosthesis Implantation | 9 | 2022 | 83 | 2.530 |
Why?
|
| Actins | 11 | 2019 | 249 | 2.530 |
Why?
|
| Stroke Volume | 34 | 2022 | 586 | 2.500 |
Why?
|
| Atrioventricular Node | 11 | 2018 | 39 | 2.420 |
Why?
|
| Cardiomyopathy, Hypertrophic | 6 | 2021 | 116 | 2.380 |
Why?
|
| rap GTP-Binding Proteins | 9 | 2010 | 11 | 2.340 |
Why?
|
| Bradycardia | 11 | 2021 | 45 | 2.290 |
Why?
|
| Hemodynamics | 14 | 2021 | 705 | 2.190 |
Why?
|
| Risk Assessment | 34 | 2022 | 2007 | 2.060 |
Why?
|
| Follow-Up Studies | 56 | 2021 | 3259 | 2.030 |
Why?
|
| Bundle of His | 7 | 2021 | 21 | 1.760 |
Why?
|
| Time Factors | 49 | 2021 | 4655 | 1.730 |
Why?
|
| rap1 GTP-Binding Proteins | 9 | 2017 | 10 | 1.580 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2023 | 931 | 1.530 |
Why?
|
| Anti-Arrhythmia Agents | 20 | 2009 | 98 | 1.520 |
Why?
|
| Cardiomyopathies | 8 | 2020 | 167 | 1.490 |
Why?
|
| Cardiology | 6 | 2022 | 140 | 1.490 |
Why?
|
| Lymphocyte Activation | 10 | 2019 | 397 | 1.400 |
Why?
|
| Lymphoma, B-Cell | 7 | 2013 | 40 | 1.400 |
Why?
|
| Echocardiography | 18 | 2020 | 515 | 1.390 |
Why?
|
| Equipment Design | 27 | 2020 | 500 | 1.370 |
Why?
|
| Equipment Failure | 11 | 2019 | 112 | 1.350 |
Why?
|
| Stroke | 13 | 2022 | 2163 | 1.310 |
Why?
|
| Animals | 91 | 2021 | 20881 | 1.290 |
Why?
|
| Signal Processing, Computer-Assisted | 8 | 2019 | 100 | 1.290 |
Why?
|
| Alzheimer Disease | 17 | 2022 | 565 | 1.270 |
Why?
|
| Exercise Test | 5 | 2019 | 242 | 1.270 |
Why?
|
| Immunological Synapses | 2 | 2019 | 3 | 1.260 |
Why?
|
| Research Design | 13 | 2020 | 729 | 1.240 |
Why?
|
| Practice Guidelines as Topic | 8 | 2018 | 772 | 1.210 |
Why?
|
| Microtubule-Organizing Center | 2 | 2018 | 2 | 1.200 |
Why?
|
| Mice | 58 | 2021 | 8474 | 1.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 16 | 2016 | 223 | 1.180 |
Why?
|
| Societies, Medical | 5 | 2017 | 403 | 1.140 |
Why?
|
| Risk Factors | 49 | 2022 | 5731 | 1.140 |
Why?
|
| Phosphoproteins | 13 | 2016 | 202 | 1.140 |
Why?
|
| Differential Threshold | 9 | 2010 | 27 | 1.130 |
Why?
|
| Anesthesia | 2 | 2018 | 120 | 1.120 |
Why?
|
| Tachycardia | 10 | 2015 | 53 | 1.120 |
Why?
|
| Heart Atria | 8 | 2015 | 206 | 1.120 |
Why?
|
| Focal Adhesion Kinase 2 | 4 | 2012 | 18 | 1.080 |
Why?
|
| Heart-Assist Devices | 4 | 2021 | 221 | 1.080 |
Why?
|
| Protein-Tyrosine Kinases | 17 | 2003 | 195 | 1.070 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2016 | 61 | 1.060 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2003 | 411 | 1.060 |
Why?
|
| United States | 44 | 2021 | 7367 | 1.050 |
Why?
|
| Atrial Flutter | 5 | 2019 | 16 | 1.050 |
Why?
|
| Prosthesis Failure | 2 | 2020 | 130 | 1.040 |
Why?
|
| Long QT Syndrome | 4 | 2016 | 14 | 1.040 |
Why?
|
| Cardiac Conduction System Disease | 7 | 2020 | 11 | 1.040 |
Why?
|
| Enzyme Activation | 26 | 2012 | 791 | 1.040 |
Why?
|
| Predictive Value of Tests | 24 | 2019 | 1465 | 1.030 |
Why?
|
| Quality of Life | 20 | 2022 | 1515 | 1.030 |
Why?
|
| Lymph Nodes | 3 | 2017 | 258 | 1.020 |
Why?
|
| Survival Rate | 16 | 2020 | 1056 | 0.990 |
Why?
|
| Anticoagulants | 5 | 2022 | 356 | 0.980 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2016 | 2223 | 0.980 |
Why?
|
| Postoperative Complications | 10 | 2019 | 1615 | 0.970 |
Why?
|
| Tachycardia, Supraventricular | 6 | 2017 | 73 | 0.970 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2017 | 161 | 0.960 |
Why?
|
| Severity of Illness Index | 18 | 2018 | 1851 | 0.960 |
Why?
|
| Quality-Adjusted Life Years | 7 | 2017 | 106 | 0.950 |
Why?
|
| Patient Selection | 13 | 2018 | 592 | 0.940 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 4848 | 0.940 |
Why?
|
| Heart Septum | 6 | 2021 | 84 | 0.930 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2018 | 189 | 0.920 |
Why?
|
| Myocardial Ischemia | 10 | 2020 | 172 | 0.900 |
Why?
|
| Protein Kinase C | 10 | 2002 | 270 | 0.890 |
Why?
|
| Secondary Prevention | 5 | 2020 | 291 | 0.890 |
Why?
|
| Cohort Studies | 24 | 2022 | 2358 | 0.890 |
Why?
|
| Registries | 9 | 2022 | 733 | 0.890 |
Why?
|
| Cell Membrane | 7 | 2019 | 525 | 0.860 |
Why?
|
| Cost-Benefit Analysis | 12 | 2017 | 504 | 0.860 |
Why?
|
| Microtubules | 3 | 2018 | 104 | 0.850 |
Why?
|
| Tricuspid Valve | 2 | 2020 | 42 | 0.840 |
Why?
|
| Phosphorylation | 27 | 2019 | 1200 | 0.820 |
Why?
|
| Adult | 61 | 2022 | 21403 | 0.810 |
Why?
|
| Ventricular Function, Right | 4 | 2020 | 103 | 0.800 |
Why?
|
| Action Potentials | 12 | 2020 | 223 | 0.790 |
Why?
|
| Double-Blind Method | 26 | 2021 | 1738 | 0.790 |
Why?
|
| Equipment Failure Analysis | 4 | 2016 | 121 | 0.780 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2015 | 57 | 0.780 |
Why?
|
| Tyrosine | 15 | 2003 | 196 | 0.780 |
Why?
|
| Anti-Bacterial Agents | 5 | 2018 | 1026 | 0.780 |
Why?
|
| Antigen-Presenting Cells | 3 | 2018 | 50 | 0.780 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2016 | 214 | 0.770 |
Why?
|
| Ventricular Premature Complexes | 1 | 2021 | 10 | 0.760 |
Why?
|
| Disease Progression | 14 | 2022 | 1038 | 0.760 |
Why?
|
| Antigen Presentation | 3 | 2018 | 76 | 0.760 |
Why?
|
| Electrodes, Implanted | 15 | 2019 | 98 | 0.750 |
Why?
|
| Defibrillators | 2 | 2020 | 11 | 0.740 |
Why?
|
| Prosthesis-Related Infections | 2 | 2018 | 70 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2012 | 331 | 0.740 |
Why?
|
| Electromagnetic Fields | 2 | 2020 | 66 | 0.730 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 7 | 2002 | 107 | 0.730 |
Why?
|
| Prognosis | 19 | 2021 | 2093 | 0.720 |
Why?
|
| Cytoskeleton | 3 | 2018 | 84 | 0.720 |
Why?
|
| GRB2 Adaptor Protein | 5 | 2016 | 13 | 0.720 |
Why?
|
| Microscopy, Fluorescence | 2 | 2018 | 261 | 0.720 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 38 | 0.700 |
Why?
|
| ras Proteins | 3 | 2018 | 102 | 0.690 |
Why?
|
| Patient Positioning | 1 | 2019 | 15 | 0.690 |
Why?
|
| Cell Line | 23 | 2017 | 1752 | 0.690 |
Why?
|
| Sensitivity and Specificity | 18 | 2017 | 1753 | 0.680 |
Why?
|
| Actin-Related Protein 3 | 1 | 2019 | 1 | 0.680 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2019 | 2 | 0.680 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2013 | 85 | 0.680 |
Why?
|
| Posture | 1 | 2019 | 107 | 0.670 |
Why?
|
| Disease Management | 4 | 2018 | 248 | 0.660 |
Why?
|
| Mice, Inbred C57BL | 13 | 2019 | 2791 | 0.660 |
Why?
|
| Heart | 11 | 2021 | 850 | 0.660 |
Why?
|
| Cardiovascular Diseases | 5 | 2015 | 940 | 0.660 |
Why?
|
| Renal Dialysis | 1 | 2020 | 174 | 0.660 |
Why?
|
| Models, Immunological | 2 | 2018 | 25 | 0.660 |
Why?
|
| Cell Polarity | 2 | 2017 | 49 | 0.650 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2009 | 25 | 0.650 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 365 | 0.650 |
Why?
|
| Ventricular Dysfunction | 2 | 2009 | 15 | 0.650 |
Why?
|
| Pulmonary Veins | 1 | 2019 | 56 | 0.650 |
Why?
|
| Anesthetists | 1 | 2018 | 5 | 0.640 |
Why?
|
| Hyperthyroidism | 1 | 2018 | 13 | 0.630 |
Why?
|
| Cardiologists | 1 | 2018 | 9 | 0.630 |
Why?
|
| Integrins | 4 | 2016 | 115 | 0.630 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 223 | 0.620 |
Why?
|
| Incidence | 13 | 2022 | 1603 | 0.620 |
Why?
|
| Immunoglobulin M | 12 | 2021 | 172 | 0.610 |
Why?
|
| Multicenter Studies as Topic | 9 | 2019 | 186 | 0.610 |
Why?
|
| Cell Communication | 2 | 2018 | 116 | 0.610 |
Why?
|
| Recurrence | 9 | 2021 | 948 | 0.600 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 62 | 0.600 |
Why?
|
| Food Hypersensitivity | 4 | 2015 | 20 | 0.590 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 69 | 0.590 |
Why?
|
| Skin Aging | 4 | 2020 | 8 | 0.590 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2017 | 12 | 0.580 |
Why?
|
| Coronary Disease | 11 | 2002 | 358 | 0.580 |
Why?
|
| Electric Injuries | 1 | 2017 | 1 | 0.580 |
Why?
|
| Cofilin 1 | 1 | 2017 | 6 | 0.580 |
Why?
|
| Pectoralis Muscles | 7 | 2007 | 12 | 0.560 |
Why?
|
| Amiodarone | 5 | 1999 | 21 | 0.560 |
Why?
|
| GTP Phosphohydrolases | 2 | 2011 | 46 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 504 | 0.550 |
Why?
|
| Proteins | 8 | 2000 | 474 | 0.550 |
Why?
|
| Ethanol | 4 | 2021 | 893 | 0.550 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 274 | 0.540 |
Why?
|
| Retrospective Studies | 19 | 2022 | 7277 | 0.530 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2016 | 83 | 0.530 |
Why?
|
| Cardiomyopathy, Dilated | 6 | 2013 | 106 | 0.530 |
Why?
|
| Leadership | 1 | 2017 | 136 | 0.520 |
Why?
|
| Models, Theoretical | 5 | 2012 | 384 | 0.520 |
Why?
|
| NF-kappa B | 6 | 2021 | 432 | 0.520 |
Why?
|
| CD40 Antigens | 3 | 2002 | 9 | 0.510 |
Why?
|
| Cell Movement | 6 | 2010 | 630 | 0.510 |
Why?
|
| Myocardium | 5 | 2006 | 1204 | 0.510 |
Why?
|
| Tumor Cells, Cultured | 16 | 2013 | 852 | 0.510 |
Why?
|
| Reproducibility of Results | 10 | 2017 | 2077 | 0.510 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 6 | 0.500 |
Why?
|
| Syncope | 5 | 2014 | 23 | 0.500 |
Why?
|
| Patient Discharge | 2 | 2021 | 294 | 0.500 |
Why?
|
| Electrodes | 4 | 2002 | 147 | 0.490 |
Why?
|
| Internationality | 1 | 2015 | 74 | 0.490 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 16 | 0.490 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2018 | 450 | 0.480 |
Why?
|
| Embolism | 4 | 2017 | 45 | 0.480 |
Why?
|
| Chemotaxis | 2 | 2012 | 38 | 0.480 |
Why?
|
| Electrophysiology | 10 | 2002 | 160 | 0.480 |
Why?
|
| Comorbidity | 8 | 2021 | 1426 | 0.470 |
Why?
|
| Isoenzymes | 6 | 2002 | 308 | 0.460 |
Why?
|
| Prosthesis Design | 5 | 2020 | 301 | 0.450 |
Why?
|
| Leukemia, B-Cell | 1 | 2013 | 7 | 0.450 |
Why?
|
| Medicare | 3 | 2021 | 319 | 0.450 |
Why?
|
| Evidence-Based Medicine | 5 | 2018 | 438 | 0.450 |
Why?
|
| Phosphotyrosine | 10 | 2006 | 41 | 0.450 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 300 | 0.440 |
Why?
|
| Dermatitis, Atopic | 2 | 2015 | 17 | 0.440 |
Why?
|
| Anaphylaxis | 5 | 2004 | 43 | 0.440 |
Why?
|
| Thiazolidinediones | 2 | 2010 | 77 | 0.440 |
Why?
|
| Young Adult | 11 | 2021 | 5717 | 0.440 |
Why?
|
| Lipopolysaccharides | 10 | 2015 | 455 | 0.440 |
Why?
|
| Endocardium | 4 | 2022 | 101 | 0.440 |
Why?
|
| beta-Alanine | 1 | 2013 | 20 | 0.430 |
Why?
|
| Antithrombins | 1 | 2013 | 32 | 0.430 |
Why?
|
| Cardiovascular Agents | 3 | 2018 | 82 | 0.430 |
Why?
|
| Oligopeptides | 1 | 2013 | 152 | 0.430 |
Why?
|
| Equipment Safety | 8 | 2015 | 50 | 0.430 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 41 | 0.420 |
Why?
|
| Ventricular Pressure | 1 | 2013 | 82 | 0.420 |
Why?
|
| Exercise | 2 | 2017 | 658 | 0.420 |
Why?
|
| Artifacts | 2 | 2016 | 125 | 0.420 |
Why?
|
| Neurodegenerative Diseases | 1 | 2013 | 102 | 0.410 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2012 | 31 | 0.410 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2012 | 27 | 0.410 |
Why?
|
| Kidney | 1 | 2017 | 945 | 0.410 |
Why?
|
| Survivors | 1 | 2014 | 256 | 0.410 |
Why?
|
| para-Aminobenzoates | 1 | 2012 | 27 | 0.410 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 1046 | 0.410 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 2011 | 34 | 0.410 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 378 | 0.410 |
Why?
|
| Sulfones | 1 | 2012 | 45 | 0.410 |
Why?
|
| Hemoglobins | 2 | 2012 | 120 | 0.400 |
Why?
|
| American Heart Association | 5 | 2018 | 142 | 0.400 |
Why?
|
| Thrombosis | 2 | 2012 | 218 | 0.400 |
Why?
|
| Benzimidazoles | 1 | 2013 | 128 | 0.400 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 186 | 0.400 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 48 | 0.400 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2011 | 16 | 0.390 |
Why?
|
| Endocarditis, Bacterial | 1 | 2011 | 32 | 0.390 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 2 | 0.390 |
Why?
|
| Fluoroscopy | 3 | 2021 | 152 | 0.390 |
Why?
|
| Hair Removal | 1 | 2011 | 2 | 0.390 |
Why?
|
| Hirsutism | 1 | 2011 | 6 | 0.390 |
Why?
|
| Multigene Family | 1 | 2011 | 93 | 0.390 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1070 | 0.390 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 47 | 0.390 |
Why?
|
| Equipment Contamination | 1 | 2011 | 38 | 0.390 |
Why?
|
| Quinolones | 1 | 2012 | 60 | 0.390 |
Why?
|
| Transcription Factors | 5 | 2021 | 753 | 0.390 |
Why?
|
| Electric Impedance | 7 | 2020 | 131 | 0.390 |
Why?
|
| Cells, Cultured | 10 | 2020 | 2673 | 0.390 |
Why?
|
| Hemorrhage | 2 | 2018 | 328 | 0.390 |
Why?
|
| Cardiac Output, Low | 3 | 2007 | 52 | 0.380 |
Why?
|
| Vena Cava, Superior | 3 | 2007 | 41 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2003 | 250 | 0.380 |
Why?
|
| Staphylococcus aureus | 2 | 2011 | 175 | 0.370 |
Why?
|
| Spleen | 3 | 2009 | 301 | 0.370 |
Why?
|
| Myocardial Contraction | 3 | 2006 | 383 | 0.370 |
Why?
|
| Administration, Oral | 7 | 2018 | 411 | 0.370 |
Why?
|
| Pyrimidines | 1 | 2012 | 178 | 0.370 |
Why?
|
| Cosmetic Techniques | 3 | 2020 | 6 | 0.370 |
Why?
|
| DNA-Binding Proteins | 3 | 2003 | 700 | 0.370 |
Why?
|
| Atrial Function | 2 | 2009 | 8 | 0.370 |
Why?
|
| Membrane Proteins | 4 | 2020 | 617 | 0.370 |
Why?
|
| Neuroprotective Agents | 1 | 2013 | 317 | 0.370 |
Why?
|
| Protein Tyrosine Phosphatases | 3 | 2016 | 56 | 0.370 |
Why?
|
| Health Services Research | 6 | 1998 | 209 | 0.360 |
Why?
|
| Survival Analysis | 10 | 2014 | 714 | 0.360 |
Why?
|
| Immunoblotting | 5 | 2015 | 254 | 0.360 |
Why?
|
| Cell Adhesion | 6 | 2012 | 324 | 0.360 |
Why?
|
| Septal Occluder Device | 2 | 2021 | 21 | 0.360 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 156 | 0.360 |
Why?
|
| Monitoring, Physiologic | 6 | 2021 | 219 | 0.350 |
Why?
|
| Myocardial Infarction | 9 | 2018 | 807 | 0.350 |
Why?
|
| Combined Modality Therapy | 7 | 2016 | 951 | 0.350 |
Why?
|
| Isoantibodies | 1 | 2009 | 35 | 0.350 |
Why?
|
| GTP-Binding Proteins | 6 | 1999 | 231 | 0.340 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2009 | 3 | 0.340 |
Why?
|
| Lysophospholipids | 2 | 2012 | 209 | 0.340 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2009 | 20 | 0.340 |
Why?
|
| Procainamide | 3 | 1999 | 12 | 0.340 |
Why?
|
| Brain Ischemia | 3 | 2022 | 665 | 0.340 |
Why?
|
| Autonomic Nervous System | 2 | 2016 | 31 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2008 | 150 | 0.330 |
Why?
|
| Chi-Square Distribution | 8 | 2018 | 546 | 0.330 |
Why?
|
| Dietary Supplements | 3 | 2016 | 332 | 0.330 |
Why?
|
| Phenethylamines | 1 | 2009 | 20 | 0.330 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 396 | 0.330 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2009 | 100 | 0.330 |
Why?
|
| Prevalence | 10 | 2020 | 1619 | 0.320 |
Why?
|
| Sphingosine | 2 | 2012 | 315 | 0.320 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 1999 | 62 | 0.320 |
Why?
|
| Apolipoproteins E | 8 | 2010 | 92 | 0.320 |
Why?
|
| Antibodies, Anti-Idiotypic | 6 | 1999 | 43 | 0.320 |
Why?
|
| Microscopy, Confocal | 5 | 2015 | 337 | 0.320 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2021 | 89 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 529 | 0.310 |
Why?
|
| Single-Blind Method | 8 | 2016 | 249 | 0.310 |
Why?
|
| Cognition Disorders | 1 | 2011 | 342 | 0.310 |
Why?
|
| Acne Vulgaris | 2 | 2021 | 11 | 0.310 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 1994 | 201 | 0.310 |
Why?
|
| Seizures, Febrile | 2 | 2020 | 10 | 0.310 |
Why?
|
| Sodium | 3 | 1995 | 161 | 0.310 |
Why?
|
| Dermatologic Agents | 2 | 2021 | 32 | 0.300 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 425 | 0.300 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 306 | 0.300 |
Why?
|
| Computer Simulation | 4 | 2018 | 706 | 0.300 |
Why?
|
| Sulfonamides | 1 | 2009 | 141 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2020 | 235 | 0.300 |
Why?
|
| Lidocaine | 2 | 2018 | 36 | 0.300 |
Why?
|
| Heart Diseases | 4 | 2018 | 276 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 147 | 0.290 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2017 | 36 | 0.290 |
Why?
|
| Cell Line, Tumor | 7 | 2023 | 1851 | 0.290 |
Why?
|
| Neuromuscular Agents | 2 | 2020 | 22 | 0.290 |
Why?
|
| Enzyme Inhibitors | 5 | 2002 | 659 | 0.290 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 792 | 0.290 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2020 | 31 | 0.290 |
Why?
|
| Autoantibodies | 1 | 2009 | 434 | 0.280 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2017 | 35 | 0.280 |
Why?
|
| Phosphatidylinositols | 9 | 1996 | 40 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 536 | 0.280 |
Why?
|
| Endpoint Determination | 4 | 2018 | 82 | 0.280 |
Why?
|
| Vagus Nerve | 3 | 2016 | 90 | 0.280 |
Why?
|
| Immunoglobulin E | 6 | 2016 | 91 | 0.280 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 1999 | 135 | 0.280 |
Why?
|
| Health Status | 6 | 2017 | 429 | 0.270 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 274 | 0.270 |
Why?
|
| Echocardiography, Stress | 1 | 2006 | 8 | 0.270 |
Why?
|
| Cause of Death | 4 | 2018 | 241 | 0.270 |
Why?
|
| Cross-Over Studies | 7 | 2021 | 260 | 0.270 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 114 | 0.260 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 124 | 0.260 |
Why?
|
| Risk | 8 | 2014 | 563 | 0.260 |
Why?
|
| Hypersensitivity | 2 | 2016 | 52 | 0.260 |
Why?
|
| Chronic Disease | 7 | 2004 | 1330 | 0.260 |
Why?
|
| Patient Participation | 1 | 2007 | 146 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 10 | 2015 | 216 | 0.260 |
Why?
|
| Decision Support Techniques | 4 | 2017 | 191 | 0.260 |
Why?
|
| Nuclear Proteins | 3 | 2019 | 271 | 0.260 |
Why?
|
| Cell Differentiation | 4 | 2008 | 1034 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2018 | 27 | 0.260 |
Why?
|
| C-Reactive Protein | 2 | 2018 | 180 | 0.260 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2018 | 15 | 0.250 |
Why?
|
| Lymphocytes | 3 | 2015 | 228 | 0.250 |
Why?
|
| Odds Ratio | 9 | 2017 | 880 | 0.250 |
Why?
|
| Protein Methyltransferases | 2 | 2016 | 5 | 0.250 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2011 | 58 | 0.250 |
Why?
|
| Systole | 4 | 2015 | 149 | 0.250 |
Why?
|
| Membrane Glycoproteins | 3 | 2000 | 370 | 0.250 |
Why?
|
| Infant | 11 | 2020 | 2891 | 0.240 |
Why?
|
| Cardiac Catheterization | 4 | 2021 | 419 | 0.240 |
Why?
|
| src Homology Domains | 4 | 2002 | 29 | 0.240 |
Why?
|
| Macrophages | 4 | 2021 | 647 | 0.240 |
Why?
|
| Logistic Models | 8 | 2017 | 1420 | 0.240 |
Why?
|
| Recovery of Function | 5 | 2020 | 506 | 0.240 |
Why?
|
| Sex Factors | 12 | 2018 | 1266 | 0.240 |
Why?
|
| Nuclear Physics | 3 | 2012 | 4 | 0.230 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 2 | 2021 | 2 | 0.230 |
Why?
|
| Lymphoma | 3 | 2018 | 116 | 0.230 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 805 | 0.230 |
Why?
|
| Abdominal Muscles | 2 | 2006 | 25 | 0.230 |
Why?
|
| Body Surface Potential Mapping | 2 | 2002 | 10 | 0.230 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 307 | 0.230 |
Why?
|
| Benzoyl Peroxide | 2 | 2021 | 7 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2018 | 848 | 0.230 |
Why?
|
| Clindamycin | 2 | 2021 | 25 | 0.230 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2003 | 11 | 0.230 |
Why?
|
| Health Care Surveys | 2 | 2018 | 239 | 0.230 |
Why?
|
| Carrier Proteins | 4 | 2002 | 597 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 12 | 0.220 |
Why?
|
| Asymptomatic Diseases | 3 | 2018 | 43 | 0.220 |
Why?
|
| Thrombin | 1 | 2003 | 117 | 0.220 |
Why?
|
| Heart Arrest | 6 | 2014 | 113 | 0.220 |
Why?
|
| Aneurysm, False | 1 | 2003 | 60 | 0.220 |
Why?
|
| Child | 18 | 2021 | 6405 | 0.220 |
Why?
|
| Milk Hypersensitivity | 2 | 2020 | 3 | 0.210 |
Why?
|
| Hospitalization | 6 | 2020 | 978 | 0.210 |
Why?
|
| Polymorphism, Genetic | 8 | 2000 | 301 | 0.210 |
Why?
|
| Coronary Artery Disease | 3 | 2007 | 696 | 0.210 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 1999 | 140 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 4 | 2020 | 532 | 0.210 |
Why?
|
| In Vitro Techniques | 7 | 2015 | 765 | 0.210 |
Why?
|
| Latex | 3 | 1991 | 3 | 0.210 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2015 | 282 | 0.210 |
Why?
|
| Linear Models | 5 | 2018 | 521 | 0.210 |
Why?
|
| Biomarkers | 7 | 2022 | 1593 | 0.210 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 2 | 2002 | 12 | 0.200 |
Why?
|
| Operative Time | 2 | 2019 | 45 | 0.200 |
Why?
|
| Antibody Formation | 2 | 2002 | 93 | 0.200 |
Why?
|
| Heart Block | 2 | 1999 | 49 | 0.200 |
Why?
|
| Homeostasis | 3 | 2009 | 291 | 0.200 |
Why?
|
| Adapalene | 1 | 2021 | 1 | 0.200 |
Why?
|
| Sodium Channels | 3 | 1997 | 24 | 0.200 |
Why?
|
| Kinetics | 8 | 2009 | 1047 | 0.200 |
Why?
|
| Australia | 4 | 2020 | 235 | 0.200 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 108 | 0.200 |
Why?
|
| Milk | 3 | 2020 | 43 | 0.200 |
Why?
|
| Diglycerides | 3 | 2009 | 49 | 0.200 |
Why?
|
| Dendritic Cells | 3 | 2011 | 201 | 0.200 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 21 | 0.200 |
Why?
|
| Life Expectancy | 2 | 2001 | 51 | 0.200 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2015 | 75 | 0.190 |
Why?
|
| Adenine | 2 | 2013 | 46 | 0.190 |
Why?
|
| Glutamates | 1 | 2021 | 41 | 0.190 |
Why?
|
| Type C Phospholipases | 6 | 2002 | 67 | 0.190 |
Why?
|
| Anti-Infective Agents | 2 | 2000 | 166 | 0.190 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2021 | 59 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 150 | 0.190 |
Why?
|
| Peptide Fragments | 5 | 2013 | 483 | 0.190 |
Why?
|
| Cytoplasm | 2 | 1999 | 155 | 0.190 |
Why?
|
| I-kappa B Proteins | 2 | 2010 | 47 | 0.190 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 63 | 0.190 |
Why?
|
| Serine | 3 | 1999 | 99 | 0.190 |
Why?
|
| Health Care Rationing | 5 | 2000 | 32 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2013 | 489 | 0.190 |
Why?
|
| Quinazolines | 2 | 2013 | 70 | 0.190 |
Why?
|
| Materials Testing | 2 | 2012 | 263 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2022 | 101 | 0.190 |
Why?
|
| Green Fluorescent Proteins | 2 | 2018 | 200 | 0.190 |
Why?
|
| Trans-Activators | 1 | 2002 | 237 | 0.190 |
Why?
|
| Sarcoidosis | 2 | 2014 | 77 | 0.190 |
Why?
|
| Cell Nucleus | 2 | 2000 | 305 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 376 | 0.190 |
Why?
|
| Bacitracin | 1 | 2000 | 1 | 0.180 |
Why?
|
| Echocardiography, Doppler | 2 | 2011 | 87 | 0.180 |
Why?
|
| Anatomic Landmarks | 1 | 2020 | 8 | 0.180 |
Why?
|
| Decision Trees | 2 | 2018 | 74 | 0.180 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2021 | 52 | 0.180 |
Why?
|
| Anesthetics, Local | 2 | 2018 | 83 | 0.180 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2000 | 16 | 0.180 |
Why?
|
| beta Catenin | 2 | 2016 | 73 | 0.180 |
Why?
|
| Vaccines | 1 | 2020 | 21 | 0.180 |
Why?
|
| Forecasting | 5 | 2020 | 277 | 0.180 |
Why?
|
| Sympathetic Nervous System | 2 | 2015 | 81 | 0.180 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 49 | 0.180 |
Why?
|
| Hydrocephalus | 1 | 2000 | 40 | 0.180 |
Why?
|
| Injections, Intralesional | 3 | 2018 | 25 | 0.180 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 12 | 0.180 |
Why?
|
| Evaluation Studies as Topic | 5 | 1997 | 219 | 0.180 |
Why?
|
| Acute-Phase Proteins | 1 | 2000 | 13 | 0.180 |
Why?
|
| Coronary Artery Bypass | 2 | 2002 | 218 | 0.180 |
Why?
|
| Elementary Particles | 2 | 2011 | 2 | 0.180 |
Why?
|
| Research | 2 | 2020 | 214 | 0.180 |
Why?
|
| Brain Mapping | 3 | 2011 | 532 | 0.180 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1999 | 22 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 1745 | 0.180 |
Why?
|
| Peptides | 2 | 2000 | 455 | 0.170 |
Why?
|
| Child, Preschool | 11 | 2020 | 3187 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 1998 | 82 | 0.170 |
Why?
|
| Melanoma, Experimental | 2 | 2011 | 95 | 0.170 |
Why?
|
| Biological Clocks | 1 | 1999 | 6 | 0.170 |
Why?
|
| Chemokine CXCL13 | 2 | 2012 | 8 | 0.170 |
Why?
|
| Circadian Rhythm | 2 | 2004 | 218 | 0.170 |
Why?
|
| Health Status Indicators | 2 | 2010 | 117 | 0.170 |
Why?
|
| Child Development | 1 | 2020 | 102 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 47 | 0.170 |
Why?
|
| Peritoneum | 2 | 2009 | 27 | 0.170 |
Why?
|
| Hypertension | 5 | 2022 | 1535 | 0.170 |
Why?
|
| Confidence Intervals | 4 | 2011 | 242 | 0.170 |
Why?
|
| Body Weight | 1 | 2001 | 554 | 0.170 |
Why?
|
| Anticonvulsants | 2 | 2013 | 223 | 0.170 |
Why?
|
| Hoof and Claw | 1 | 1999 | 3 | 0.170 |
Why?
|
| Apoptosis | 4 | 2013 | 1641 | 0.170 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 114 | 0.170 |
Why?
|
| Wireless Technology | 1 | 2019 | 4 | 0.170 |
Why?
|
| Horses | 1 | 1999 | 20 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2021 | 158 | 0.170 |
Why?
|
| Nervous System | 1 | 1999 | 45 | 0.170 |
Why?
|
| Cell Compartmentation | 1 | 2019 | 41 | 0.170 |
Why?
|
| Adolescent | 15 | 2021 | 8912 | 0.170 |
Why?
|
| Nanomedicine | 1 | 2019 | 19 | 0.170 |
Why?
|
| Cell Division | 5 | 2003 | 541 | 0.170 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 64 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 1536 | 0.160 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 58 | 0.160 |
Why?
|
| Retroviridae | 1 | 1999 | 29 | 0.160 |
Why?
|
| Protein Sorting Signals | 1 | 1998 | 11 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 170 | 0.160 |
Why?
|
| Affect | 2 | 2021 | 218 | 0.160 |
Why?
|
| Diaphragm | 1 | 1998 | 22 | 0.160 |
Why?
|
| Electrocoagulation | 1 | 1998 | 35 | 0.160 |
Why?
|
| Thoracic Injuries | 1 | 1999 | 44 | 0.160 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 4 | 0.160 |
Why?
|
| Antigens, CD | 3 | 2002 | 230 | 0.160 |
Why?
|
| Tissue Adhesives | 1 | 2018 | 17 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2019 | 77 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 120 | 0.160 |
Why?
|
| Hospital Charges | 1 | 1998 | 60 | 0.160 |
Why?
|
| Palliative Care | 2 | 2012 | 271 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 176 | 0.160 |
Why?
|
| Nasolabial Fold | 1 | 2018 | 1 | 0.160 |
Why?
|
| Dermal Fillers | 1 | 2018 | 3 | 0.160 |
Why?
|
| Athletes | 1 | 2018 | 40 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 81 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 150 | 0.160 |
Why?
|
| Deep Sedation | 1 | 2018 | 11 | 0.160 |
Why?
|
| Suture Techniques | 1 | 2018 | 75 | 0.160 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2019 | 103 | 0.160 |
Why?
|
| Models, Economic | 2 | 1999 | 69 | 0.160 |
Why?
|
| Evoked Potentials, Motor | 1 | 1998 | 63 | 0.160 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2001 | 19 | 0.160 |
Why?
|
| Parkinson Disease | 2 | 2011 | 272 | 0.160 |
Why?
|
| Protective Factors | 1 | 2018 | 24 | 0.150 |
Why?
|
| Case-Control Studies | 8 | 2020 | 1553 | 0.150 |
Why?
|
| Nociceptors | 2 | 2013 | 9 | 0.150 |
Why?
|
| Cytokines | 4 | 2021 | 866 | 0.150 |
Why?
|
| Models, Cardiovascular | 2 | 2015 | 133 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2018 | 145 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1999 | 131 | 0.150 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 173 | 0.150 |
Why?
|
| Endarterectomy, Carotid | 1 | 1998 | 110 | 0.150 |
Why?
|
| Protein Conformation | 1 | 2019 | 362 | 0.150 |
Why?
|
| Cicatrix | 1 | 2018 | 60 | 0.150 |
Why?
|
| Longevity | 1 | 1998 | 60 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2005 | 319 | 0.150 |
Why?
|
| Molecular Probe Techniques | 1 | 2017 | 7 | 0.150 |
Why?
|
| Body Height | 1 | 2018 | 67 | 0.150 |
Why?
|
| Lysophosphatidylcholines | 1 | 1997 | 11 | 0.150 |
Why?
|
| Molecular Probes | 1 | 2017 | 27 | 0.150 |
Why?
|
| Models, Biological | 3 | 2017 | 981 | 0.150 |
Why?
|
| COS Cells | 1 | 2018 | 155 | 0.150 |
Why?
|
| Software | 1 | 2020 | 418 | 0.150 |
Why?
|
| Protein Binding | 5 | 2001 | 1027 | 0.150 |
Why?
|
| Sodium Channel Blockers | 1 | 1997 | 23 | 0.150 |
Why?
|
| Intraoperative Complications | 3 | 1998 | 129 | 0.150 |
Why?
|
| Physician's Role | 1 | 2018 | 116 | 0.150 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 138 | 0.150 |
Why?
|
| Quantum Dots | 1 | 2017 | 29 | 0.150 |
Why?
|
| Treatment Failure | 3 | 2019 | 216 | 0.150 |
Why?
|
| Epidemiologic Methods | 1 | 1997 | 83 | 0.150 |
Why?
|
| Workload | 1 | 2018 | 103 | 0.150 |
Why?
|
| Propanolamines | 2 | 2002 | 70 | 0.150 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 649 | 0.150 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Diagnosis, Differential | 5 | 2002 | 1140 | 0.140 |
Why?
|
| Genotype | 9 | 2010 | 786 | 0.140 |
Why?
|
| Neuropsychological Tests | 3 | 2022 | 517 | 0.140 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.140 |
Why?
|
| Hot Temperature | 1 | 1997 | 152 | 0.140 |
Why?
|
| Dyneins | 1 | 2017 | 10 | 0.140 |
Why?
|
| Sex Distribution | 3 | 2009 | 274 | 0.140 |
Why?
|
| Professionalism | 1 | 2017 | 28 | 0.140 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 5 | 0.140 |
Why?
|
| Glycogen Synthase Kinases | 3 | 2002 | 6 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 109 | 0.140 |
Why?
|
| Immunoglobulins | 2 | 1994 | 97 | 0.140 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 206 | 0.140 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2021 | 413 | 0.140 |
Why?
|
| Retroperitoneal Space | 1 | 2016 | 7 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 511 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2002 | 64 | 0.140 |
Why?
|
| Public Health Administration | 1 | 1997 | 36 | 0.140 |
Why?
|
| Respiratory Function Tests | 2 | 2014 | 123 | 0.140 |
Why?
|
| Drug Therapy | 1 | 1997 | 71 | 0.140 |
Why?
|
| Medically Uninsured | 3 | 1993 | 99 | 0.140 |
Why?
|
| Alleles | 7 | 2010 | 386 | 0.140 |
Why?
|
| Fibroblasts | 1 | 2021 | 902 | 0.140 |
Why?
|
| Lung | 1 | 2021 | 849 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2016 | 12 | 0.140 |
Why?
|
| Molecular Sequence Data | 8 | 2001 | 1447 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2016 | 9 | 0.140 |
Why?
|
| Escherichia coli Proteins | 1 | 1996 | 65 | 0.140 |
Why?
|
| Rejuvenation | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cryotherapy | 1 | 2016 | 36 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 475 | 0.140 |
Why?
|
| Immunization, Secondary | 2 | 2018 | 17 | 0.140 |
Why?
|
| Cell Survival | 5 | 2010 | 901 | 0.140 |
Why?
|
| Sclerotherapy | 1 | 2016 | 10 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 1997 | 123 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2017 | 111 | 0.140 |
Why?
|
| Phorbol Esters | 3 | 2003 | 37 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 114 | 0.140 |
Why?
|
| Amino Acid Sequence | 7 | 2001 | 1083 | 0.140 |
Why?
|
| Mortality | 2 | 1996 | 163 | 0.140 |
Why?
|
| Varicose Veins | 1 | 2016 | 11 | 0.140 |
Why?
|
| Prebiotics | 1 | 2016 | 10 | 0.140 |
Why?
|
| Machine Learning | 1 | 2018 | 170 | 0.130 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 30 | 0.130 |
Why?
|
| Causality | 1 | 2016 | 82 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 1997 | 86 | 0.130 |
Why?
|
| Eczema | 1 | 2016 | 10 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 72 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 91 | 0.130 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2015 | 4 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2016 | 54 | 0.130 |
Why?
|
| Wnt Proteins | 1 | 2016 | 57 | 0.130 |
Why?
|
| Infant Formula | 1 | 2016 | 24 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2016 | 99 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2018 | 311 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 369 | 0.130 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2015 | 13 | 0.130 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2015 | 1 | 0.130 |
Why?
|
| Managed Care Programs | 1 | 1995 | 45 | 0.130 |
Why?
|
| Protons | 2 | 2012 | 57 | 0.130 |
Why?
|
| Pain | 1 | 1999 | 472 | 0.130 |
Why?
|
| Europe | 6 | 2015 | 196 | 0.130 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 208 | 0.130 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2015 | 41 | 0.130 |
Why?
|
| Subcutaneous Tissue | 2 | 2012 | 6 | 0.130 |
Why?
|
| Binding Sites | 5 | 2000 | 631 | 0.130 |
Why?
|
| Skin Tests | 2 | 2012 | 30 | 0.130 |
Why?
|
| Atrial Pressure | 1 | 2015 | 9 | 0.130 |
Why?
|
| Protein Transport | 3 | 2017 | 280 | 0.130 |
Why?
|
| Age Factors | 8 | 2017 | 1864 | 0.130 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.130 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2006 | 45 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2006 | 52 | 0.130 |
Why?
|
| Apolipoprotein E4 | 4 | 2011 | 31 | 0.130 |
Why?
|
| Acidosis | 1 | 1995 | 31 | 0.120 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 86 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 1033 | 0.120 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2014 | 4 | 0.120 |
Why?
|
| Chickenpox Vaccine | 1 | 2014 | 5 | 0.120 |
Why?
|
| Rats | 6 | 2013 | 5300 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 434 | 0.120 |
Why?
|
| Delivery of Health Care | 2 | 1997 | 445 | 0.120 |
Why?
|
| Extracellular Space | 1 | 1995 | 121 | 0.120 |
Why?
|
| Gene Expression Regulation | 4 | 2002 | 1293 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 13 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 56 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 154 | 0.120 |
Why?
|
| Social Values | 3 | 2000 | 34 | 0.120 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 215 | 0.120 |
Why?
|
| Coronary Vessels | 3 | 2005 | 313 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 1 | 2015 | 84 | 0.120 |
Why?
|
| Gene Knock-In Techniques | 2 | 2015 | 35 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 148 | 0.120 |
Why?
|
| Tachycardia, Paroxysmal | 2 | 2004 | 4 | 0.120 |
Why?
|
| Calcium | 5 | 1993 | 929 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1994 | 78 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 597 | 0.120 |
Why?
|
| Receptors, Cytokine | 1 | 1994 | 19 | 0.120 |
Why?
|
| Patient Safety | 1 | 2016 | 202 | 0.120 |
Why?
|
| Blood Pressure | 4 | 2013 | 1451 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2014 | 79 | 0.110 |
Why?
|
| Ligands | 1 | 2015 | 317 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1994 | 41 | 0.110 |
Why?
|
| Anesthesia, Epidural | 1 | 1993 | 11 | 0.110 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 79 | 0.110 |
Why?
|
| Toxicity Tests | 1 | 2013 | 26 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 451 | 0.110 |
Why?
|
| Cortical Spreading Depression | 1 | 2013 | 1 | 0.110 |
Why?
|
| Trigeminal Ganglion | 1 | 2013 | 5 | 0.110 |
Why?
|
| Phenylenediamines | 1 | 2013 | 16 | 0.110 |
Why?
|
| Maryland | 2 | 2004 | 77 | 0.110 |
Why?
|
| Glycosides | 1 | 2013 | 14 | 0.110 |
Why?
|
| Phosphotransferases | 2 | 1992 | 16 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1054 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2000 | 742 | 0.110 |
Why?
|
| Family | 3 | 2015 | 293 | 0.110 |
Why?
|
| Telemetry | 1 | 2013 | 23 | 0.110 |
Why?
|
| Carbamates | 1 | 2013 | 41 | 0.110 |
Why?
|
| Dabigatran | 1 | 2013 | 35 | 0.110 |
Why?
|
| Neutrons | 1 | 2012 | 5 | 0.110 |
Why?
|
| GTPase-Activating Proteins | 3 | 2015 | 21 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2013 | 149 | 0.110 |
Why?
|
| Phospholipase C gamma | 3 | 2002 | 13 | 0.110 |
Why?
|
| Desipramine | 1 | 1992 | 47 | 0.110 |
Why?
|
| Triterpenes | 1 | 2013 | 40 | 0.110 |
Why?
|
| Self Care | 1 | 2015 | 253 | 0.100 |
Why?
|
| Cadherins | 1 | 2013 | 93 | 0.100 |
Why?
|
| School Health Services | 2 | 2004 | 72 | 0.100 |
Why?
|
| Serologic Tests | 1 | 2012 | 46 | 0.100 |
Why?
|
| Chemotactic Factors | 1 | 2012 | 14 | 0.100 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 2000 | 102 | 0.100 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2012 | 30 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 514 | 0.100 |
Why?
|
| Physicians | 1 | 1995 | 324 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 118 | 0.100 |
Why?
|
| Physics | 1 | 2011 | 9 | 0.100 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1991 | 20 | 0.100 |
Why?
|
| Asthma | 4 | 2012 | 345 | 0.100 |
Why?
|
| Transfection | 3 | 2011 | 782 | 0.100 |
Why?
|
| Lung Diseases | 1 | 1993 | 175 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 135 | 0.100 |
Why?
|
| Databases, Bibliographic | 1 | 2011 | 14 | 0.100 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 12 | 0.100 |
Why?
|
| Mice, Inbred DBA | 3 | 1999 | 120 | 0.100 |
Why?
|
| Amiloride | 1 | 1991 | 22 | 0.100 |
Why?
|
| Advisory Committees | 3 | 2022 | 73 | 0.100 |
Why?
|
| Apathy | 1 | 2011 | 28 | 0.100 |
Why?
|
| Receptors, Fc | 1 | 1991 | 19 | 0.100 |
Why?
|
| Fibrosis | 1 | 2013 | 371 | 0.100 |
Why?
|
| Probability | 2 | 2008 | 245 | 0.100 |
Why?
|
| Face | 1 | 2011 | 46 | 0.100 |
Why?
|
| Respiration | 1 | 1991 | 91 | 0.100 |
Why?
|
| Interview, Psychological | 2 | 2010 | 113 | 0.090 |
Why?
|
| Oncogene Proteins | 2 | 2003 | 35 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 75 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 446 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 2083 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1991 | 150 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 27 | 0.090 |
Why?
|
| Phosphatidylinositol Phosphates | 3 | 2016 | 6 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 710 | 0.090 |
Why?
|
| Nasopharyngitis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Extracellular Matrix | 2 | 2016 | 493 | 0.090 |
Why?
|
| Indans | 1 | 2010 | 20 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 91 | 0.090 |
Why?
|
| Sample Size | 2 | 2021 | 79 | 0.090 |
Why?
|
| Intelligence Tests | 1 | 2010 | 32 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2003 | 312 | 0.090 |
Why?
|
| Gloves, Surgical | 1 | 1990 | 5 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 621 | 0.090 |
Why?
|
| Cell Cycle Proteins | 3 | 2016 | 230 | 0.090 |
Why?
|
| Cell Shape | 1 | 2010 | 37 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2011 | 100 | 0.090 |
Why?
|
| Educational Status | 3 | 2009 | 273 | 0.090 |
Why?
|
| Enzyme Precursors | 3 | 2002 | 27 | 0.090 |
Why?
|
| South Carolina | 1 | 2017 | 2752 | 0.090 |
Why?
|
| Edema | 1 | 2010 | 66 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2 | 2001 | 8 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 331 | 0.090 |
Why?
|
| Safety | 2 | 2003 | 145 | 0.090 |
Why?
|
| Calibration | 1 | 2010 | 73 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2002 | 334 | 0.090 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2000 | 21 | 0.090 |
Why?
|
| Piperidines | 1 | 2010 | 123 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2010 | 95 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2009 | 18 | 0.090 |
Why?
|
| North America | 3 | 2015 | 112 | 0.090 |
Why?
|
| Dissent and Disputes | 1 | 2009 | 5 | 0.090 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 150 | 0.090 |
Why?
|
| Mass Spectrometry | 3 | 2015 | 284 | 0.090 |
Why?
|
| Gene Expression | 4 | 2010 | 770 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2011 | 122 | 0.090 |
Why?
|
| Placebo Effect | 1 | 2009 | 20 | 0.090 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1999 | 15 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 207 | 0.080 |
Why?
|
| Vaccination | 1 | 2011 | 189 | 0.080 |
Why?
|
| Omentum | 1 | 2009 | 18 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 160 | 0.080 |
Why?
|
| Patient Readmission | 3 | 2019 | 267 | 0.080 |
Why?
|
| Threonine | 2 | 1999 | 47 | 0.080 |
Why?
|
| Shc Signaling Adaptor Proteins | 2 | 1999 | 26 | 0.080 |
Why?
|
| Arachis | 1 | 1989 | 8 | 0.080 |
Why?
|
| Hypersensitivity, Immediate | 1 | 1989 | 13 | 0.080 |
Why?
|
| Rhode Island | 1 | 2009 | 9 | 0.080 |
Why?
|
| Cardiac Output | 3 | 1999 | 133 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 2009 | 90 | 0.080 |
Why?
|
| Neuralgia | 1 | 2009 | 27 | 0.080 |
Why?
|
| Pregnancy | 3 | 2016 | 2334 | 0.080 |
Why?
|
| Drug Combinations | 3 | 2021 | 304 | 0.080 |
Why?
|
| Triazines | 1 | 2009 | 48 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 1991 | 384 | 0.080 |
Why?
|
| Postoperative Period | 3 | 2018 | 238 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1994 | 381 | 0.080 |
Why?
|
| Androstadienes | 3 | 1998 | 41 | 0.080 |
Why?
|
| beta-Lactamase Inhibitors | 2 | 2000 | 9 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 266 | 0.080 |
Why?
|
| Heart Transplantation | 2 | 2004 | 328 | 0.080 |
Why?
|
| Collagen | 2 | 2016 | 636 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2011 | 2800 | 0.080 |
Why?
|
| Patient Care Management | 2 | 2018 | 40 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1174 | 0.080 |
Why?
|
| Pre-B Cell Receptors | 1 | 2008 | 1 | 0.080 |
Why?
|
| Boronic Acids | 2 | 2000 | 40 | 0.080 |
Why?
|
| Sick Sinus Syndrome | 2 | 2019 | 18 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2001 | 285 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2004 | 349 | 0.080 |
Why?
|
| Age Distribution | 1 | 2009 | 320 | 0.080 |
Why?
|
| Allergens | 2 | 2020 | 54 | 0.080 |
Why?
|
| Delayed-Action Preparations | 3 | 2013 | 120 | 0.080 |
Why?
|
| Glucose | 1 | 2010 | 307 | 0.080 |
Why?
|
| Catheterization, Central Venous | 2 | 1999 | 89 | 0.080 |
Why?
|
| Resource Allocation | 2 | 1999 | 35 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2010 | 287 | 0.080 |
Why?
|
| Particle Accelerators | 1 | 2007 | 10 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 179 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 236 | 0.070 |
Why?
|
| Photons | 1 | 2007 | 32 | 0.070 |
Why?
|
| Forehead | 2 | 2020 | 13 | 0.070 |
Why?
|
| Guanosine Triphosphate | 3 | 2016 | 65 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 362 | 0.070 |
Why?
|
| Mental Status Schedule | 1 | 2007 | 31 | 0.070 |
Why?
|
| Cattle | 2 | 2020 | 475 | 0.070 |
Why?
|
| Mutation | 5 | 2015 | 1213 | 0.070 |
Why?
|
| Glycerides | 1 | 1987 | 18 | 0.070 |
Why?
|
| Sports | 1 | 2007 | 55 | 0.070 |
Why?
|
| Cardiomegaly | 2 | 2002 | 213 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 326 | 0.070 |
Why?
|
| Vaccines, Combined | 2 | 2018 | 8 | 0.070 |
Why?
|
| Canada | 3 | 2021 | 267 | 0.070 |
Why?
|
| Global Health | 2 | 2018 | 136 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2016 | 237 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2018 | 1040 | 0.070 |
Why?
|
| Placebos | 1 | 2007 | 195 | 0.070 |
Why?
|
| Foreign-Body Migration | 2 | 1997 | 38 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2006 | 71 | 0.070 |
Why?
|
| Macrophage Activation | 2 | 2000 | 75 | 0.070 |
Why?
|
| Stem Cells | 1 | 2008 | 248 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 306 | 0.070 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2006 | 63 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 279 | 0.070 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2010 | 28 | 0.070 |
Why?
|
| Enzyme Induction | 1 | 2006 | 119 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 213 | 0.070 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 168 | 0.060 |
Why?
|
| Galantamine | 1 | 2005 | 9 | 0.060 |
Why?
|
| Syk Kinase | 3 | 2002 | 10 | 0.060 |
Why?
|
| Statistics as Topic | 3 | 2010 | 219 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 283 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2003 | 251 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 175 | 0.060 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 2 | 1999 | 6 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 756 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2013 | 202 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2016 | 1692 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 258 | 0.060 |
Why?
|
| Gels | 2 | 2016 | 55 | 0.060 |
Why?
|
| Methylation | 2 | 2016 | 56 | 0.060 |
Why?
|
| Intercellular Junctions | 2 | 2016 | 32 | 0.060 |
Why?
|
| Brain | 2 | 2010 | 2176 | 0.060 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 33 | 0.060 |
Why?
|
| Length of Stay | 3 | 2012 | 780 | 0.060 |
Why?
|
| Reference Values | 3 | 2000 | 579 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2019 | 867 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 567 | 0.060 |
Why?
|
| Depression | 1 | 2011 | 943 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 468 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2019 | 622 | 0.060 |
Why?
|
| Sinoatrial Node | 1 | 2004 | 14 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2004 | 82 | 0.060 |
Why?
|
| Matched-Pair Analysis | 1 | 2004 | 25 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 34 | 0.060 |
Why?
|
| Insurance, Health | 3 | 1996 | 201 | 0.060 |
Why?
|
| Pancreatic Function Tests | 1 | 2003 | 6 | 0.060 |
Why?
|
| Focal Adhesions | 2 | 2016 | 25 | 0.060 |
Why?
|
| Macromolecular Substances | 2 | 1995 | 122 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2005 | 206 | 0.060 |
Why?
|
| Furans | 1 | 2003 | 27 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2003 | 113 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2023 | 17 | 0.060 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2023 | 17 | 0.050 |
Why?
|
| Electric Conductivity | 2 | 1995 | 87 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2002 | 562 | 0.050 |
Why?
|
| Nuclear Energy | 2 | 2012 | 3 | 0.050 |
Why?
|
| Receptor Aggregation | 3 | 1992 | 4 | 0.050 |
Why?
|
| Adenosine | 1 | 2003 | 165 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 217 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2018 | 159 | 0.050 |
Why?
|
| Receptors, Antigen | 2 | 1994 | 6 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 194 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 267 | 0.050 |
Why?
|
| Escherichia coli | 3 | 2000 | 368 | 0.050 |
Why?
|
| Movement | 1 | 2003 | 179 | 0.050 |
Why?
|
| Epicardial Mapping | 1 | 2022 | 4 | 0.050 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2002 | 28 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2009 | 737 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 50 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 39 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 129 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2002 | 69 | 0.050 |
Why?
|
| Sympatholytics | 1 | 2002 | 11 | 0.050 |
Why?
|
| Parasympatholytics | 1 | 2002 | 19 | 0.050 |
Why?
|
| Parasympathetic Nervous System | 1 | 2002 | 14 | 0.050 |
Why?
|
| Chemokine CXCL12 | 1 | 2002 | 51 | 0.050 |
Why?
|
| Atropine | 1 | 2002 | 29 | 0.050 |
Why?
|
| Radioallergosorbent Test | 3 | 1991 | 5 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2002 | 12 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2023 | 304 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2002 | 1664 | 0.050 |
Why?
|
| Mast Cells | 2 | 2011 | 113 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 25 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2016 | 2455 | 0.050 |
Why?
|
| Phorbol 12,13-Dibutyrate | 2 | 1999 | 24 | 0.050 |
Why?
|
| Base Sequence | 3 | 1999 | 1015 | 0.050 |
Why?
|
| Association Learning | 1 | 1981 | 36 | 0.050 |
Why?
|
| Inflammation | 2 | 2021 | 1030 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2021 | 111 | 0.050 |
Why?
|
| Ionomycin | 2 | 1999 | 24 | 0.050 |
Why?
|
| Pericardium | 1 | 2022 | 97 | 0.050 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 10 | 0.050 |
Why?
|
| Bacteriophage lambda | 1 | 2001 | 7 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 1173 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 138 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2002 | 87 | 0.050 |
Why?
|
| Immunoglobulin D | 2 | 1991 | 14 | 0.050 |
Why?
|
| Introns | 2 | 1999 | 68 | 0.050 |
Why?
|
| Protein Folding | 1 | 2001 | 82 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 307 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2001 | 85 | 0.050 |
Why?
|
| Membrane Potentials | 2 | 1991 | 200 | 0.050 |
Why?
|
| Selection Bias | 1 | 2000 | 23 | 0.050 |
Why?
|
| Facial Muscles | 1 | 2020 | 11 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2022 | 136 | 0.050 |
Why?
|
| Esthetics | 1 | 2020 | 18 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 44 | 0.050 |
Why?
|
| beta-Lactamases | 2 | 2000 | 33 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 131 | 0.050 |
Why?
|
| Salmonella Infections, Animal | 1 | 2000 | 5 | 0.050 |
Why?
|
| Chick Embryo | 2 | 1991 | 379 | 0.050 |
Why?
|
| Salmonella typhimurium | 1 | 2000 | 15 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 481 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 1998 | 22 | 0.050 |
Why?
|
| British Columbia | 1 | 2020 | 3 | 0.040 |
Why?
|
| Milk Proteins | 1 | 2020 | 22 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 1998 | 33 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2020 | 59 | 0.040 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 1999 | 1 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2000 | 38 | 0.040 |
Why?
|
| Teichoic Acids | 1 | 1999 | 7 | 0.040 |
Why?
|
| Gastrointestinal Motility | 1 | 2020 | 52 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 3 | 1989 | 60 | 0.040 |
Why?
|
| Steroids | 1 | 2000 | 84 | 0.040 |
Why?
|
| CD79 Antigens | 3 | 2002 | 5 | 0.040 |
Why?
|
| Gram-Positive Bacteria | 1 | 1999 | 23 | 0.040 |
Why?
|
| Lipids | 1 | 2021 | 298 | 0.040 |
Why?
|
| Meperidine | 1 | 1999 | 5 | 0.040 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1999 | 8 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2000 | 165 | 0.040 |
Why?
|
| Anesthesia Recovery Period | 1 | 1999 | 11 | 0.040 |
Why?
|
| Exercise Tolerance | 2 | 2013 | 75 | 0.040 |
Why?
|
| Phospholipases A | 1 | 1999 | 41 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 88 | 0.040 |
Why?
|
| Estrenes | 1 | 1999 | 2 | 0.040 |
Why?
|
| alpha-Macroglobulins | 1 | 1999 | 8 | 0.040 |
Why?
|
| Mycobacterium smegmatis | 1 | 2019 | 5 | 0.040 |
Why?
|
| Contraceptives, Oral | 1 | 1999 | 28 | 0.040 |
Why?
|
| Hemostasis | 1 | 1999 | 32 | 0.040 |
Why?
|
| Single Molecule Imaging | 1 | 2019 | 6 | 0.040 |
Why?
|
| Protein Kinase C-delta | 1 | 1999 | 12 | 0.040 |
Why?
|
| Learning | 1 | 1981 | 186 | 0.040 |
Why?
|
| Neurobiology | 1 | 1999 | 9 | 0.040 |
Why?
|
| Methods | 2 | 1996 | 156 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 1999 | 15 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2011 | 800 | 0.040 |
Why?
|
| Protein Kinases | 2 | 1998 | 122 | 0.040 |
Why?
|
| Lipid Bilayers | 1 | 2019 | 24 | 0.040 |
Why?
|
| Midazolam | 1 | 1999 | 46 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 238 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 163 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2019 | 50 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2019 | 118 | 0.040 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 1999 | 14 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 1999 | 25 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 32 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2002 | 682 | 0.040 |
Why?
|
| Peptide Mapping | 1 | 1999 | 39 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1994 | 272 | 0.040 |
Why?
|
| Cytosol | 1 | 2019 | 123 | 0.040 |
Why?
|
| Biological Transport | 1 | 1999 | 210 | 0.040 |
Why?
|
| Valsalva Maneuver | 1 | 1998 | 10 | 0.040 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 1998 | 1 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 1999 | 91 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 1999 | 96 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 1999 | 57 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1998 | 19 | 0.040 |
Why?
|
| Wound Closure Techniques | 1 | 2018 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 1998 | 4 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2018 | 20 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 1999 | 107 | 0.040 |
Why?
|
| Societies | 1 | 2018 | 15 | 0.040 |
Why?
|
| tau Proteins | 1 | 1999 | 61 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 420 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 1999 | 130 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 92 | 0.040 |
Why?
|
| Adenylate Cyclase Toxin | 2 | 1989 | 12 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2021 | 253 | 0.040 |
Why?
|
| Butyrylcholinesterase | 1 | 1998 | 9 | 0.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2009 | 95 | 0.040 |
Why?
|
| Cholera Toxin | 2 | 1989 | 30 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 71 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 99 | 0.040 |
Why?
|
| Pertussis Toxin | 2 | 1989 | 72 | 0.040 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2018 | 40 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1998 | 90 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 43 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 1999 | 100 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 1998 | 15 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 1998 | 46 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 193 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 138 | 0.040 |
Why?
|
| Spinal Cord | 1 | 1999 | 244 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 1342 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1999 | 171 | 0.040 |
Why?
|
| Models, Molecular | 4 | 2002 | 546 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 1998 | 50 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 1999 | 94 | 0.040 |
Why?
|
| Gene Frequency | 4 | 2000 | 207 | 0.040 |
Why?
|
| Benzophenanthridines | 1 | 1997 | 5 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1998 | 40 | 0.040 |
Why?
|
| Phenanthridines | 1 | 1997 | 8 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 1997 | 27 | 0.040 |
Why?
|
| Chickens | 1 | 1998 | 232 | 0.040 |
Why?
|
| Anesthesia, Intravenous | 1 | 1997 | 12 | 0.040 |
Why?
|
| Antigens | 2 | 1995 | 90 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 130 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 1998 | 46 | 0.040 |
Why?
|
| Thermodynamics | 2 | 2012 | 162 | 0.040 |
Why?
|
| Thromboembolism | 1 | 1998 | 91 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2003 | 2324 | 0.040 |
Why?
|
| Alkaloids | 1 | 1997 | 40 | 0.040 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1997 | 7 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2017 | 144 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1999 | 284 | 0.040 |
Why?
|
| Carotid Stenosis | 1 | 1998 | 163 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 1999 | 340 | 0.040 |
Why?
|
| Body Constitution | 1 | 1997 | 24 | 0.040 |
Why?
|
| Cellular Apoptosis Susceptibility Protein | 1 | 1996 | 1 | 0.040 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 1997 | 7 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-crk | 1 | 1996 | 3 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2016 | 6 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 1997 | 204 | 0.040 |
Why?
|
| Exudates and Transudates | 1 | 1997 | 25 | 0.040 |
Why?
|
| Protozoan Proteins | 1 | 1996 | 25 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1996 | 12 | 0.040 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1997 | 20 | 0.040 |
Why?
|
| Lipolysis | 1 | 2016 | 13 | 0.040 |
Why?
|
| Work | 1 | 1996 | 12 | 0.040 |
Why?
|
| Thigh | 1 | 2016 | 27 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 1997 | 72 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 1997 | 41 | 0.030 |
Why?
|
| Hematoma | 1 | 1997 | 47 | 0.030 |
Why?
|
| Nausea | 1 | 1996 | 47 | 0.030 |
Why?
|
| Dermatophagoides farinae | 1 | 2016 | 1 | 0.030 |
Why?
|
| Acetamides | 1 | 1996 | 17 | 0.030 |
Why?
|
| Molecular Weight | 3 | 1992 | 358 | 0.030 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2016 | 4 | 0.030 |
Why?
|
| Cellulite | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pseudopodia | 1 | 2016 | 16 | 0.030 |
Why?
|
| Lipectomy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2016 | 28 | 0.030 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Vinculin | 1 | 2016 | 15 | 0.030 |
Why?
|
| Polymerization | 1 | 2016 | 17 | 0.030 |
Why?
|
| Axin Protein | 1 | 2016 | 6 | 0.030 |
Why?
|
| Health Resources | 1 | 1997 | 76 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 786 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 23 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 1998 | 615 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2016 | 37 | 0.030 |
Why?
|
| Loratadine | 1 | 1996 | 4 | 0.030 |
Why?
|
| Independent Practice Associations | 1 | 1995 | 2 | 0.030 |
Why?
|
| Preferred Provider Organizations | 1 | 1995 | 2 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1996 | 134 | 0.030 |
Why?
|
| Capitation Fee | 1 | 1995 | 4 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 80 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 90 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 1995 | 22 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 234 | 0.030 |
Why?
|
| Palatine Tonsil | 1 | 2015 | 8 | 0.030 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 1996 | 22 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 1996 | 86 | 0.030 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1997 | 140 | 0.030 |
Why?
|
| Utilization Review | 1 | 1995 | 48 | 0.030 |
Why?
|
| Salaries and Fringe Benefits | 1 | 1995 | 29 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 40 | 0.030 |
Why?
|
| Anti-Allergic Agents | 1 | 1996 | 27 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 57 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 1998 | 261 | 0.030 |
Why?
|
| Intestines | 1 | 2016 | 114 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2015 | 119 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 377 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2016 | 117 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 166 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2015 | 85 | 0.030 |
Why?
|
| Radiography | 1 | 1997 | 572 | 0.030 |
Why?
|
| Health Services Accessibility | 2 | 1999 | 581 | 0.030 |
Why?
|
| Troponin T | 1 | 2015 | 16 | 0.030 |
Why?
|
| Inositol Phosphates | 3 | 1992 | 28 | 0.030 |
Why?
|
| Publishing | 1 | 1996 | 89 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 1992 | 88 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 139 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2015 | 46 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 1996 | 239 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 266 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 1998 | 225 | 0.030 |
Why?
|
| Leg | 1 | 2016 | 191 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 124 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 368 | 0.030 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 3 | 0.030 |
Why?
|
| Son of Sevenless Proteins | 1 | 1994 | 4 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 211 | 0.030 |
Why?
|
| Epilepsy | 1 | 2018 | 336 | 0.030 |
Why?
|
| Streptomyces | 1 | 1994 | 15 | 0.030 |
Why?
|
| Patient Admission | 2 | 2012 | 99 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 67 | 0.030 |
Why?
|
| Troponin | 1 | 2014 | 25 | 0.030 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 1994 | 9 | 0.030 |
Why?
|
| Phosphopeptides | 1 | 1994 | 8 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 1994 | 14 | 0.030 |
Why?
|
| Thermodilution | 1 | 1994 | 20 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1994 | 22 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 56 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 1994 | 39 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 1999 | 498 | 0.030 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 1994 | 2 | 0.030 |
Why?
|
| Data Collection | 1 | 1995 | 420 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 1994 | 63 | 0.030 |
Why?
|
| Mitogens | 1 | 1994 | 45 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1995 | 112 | 0.030 |
Why?
|
| Metoprolol | 1 | 1993 | 8 | 0.030 |
Why?
|
| Isosorbide Dinitrate | 1 | 1993 | 6 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1994 | 69 | 0.030 |
Why?
|
| Electric Stimulation | 2 | 1992 | 218 | 0.030 |
Why?
|
| Diltiazem | 1 | 1993 | 26 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1994 | 101 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 114 | 0.030 |
Why?
|
| Walking | 2 | 2010 | 241 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 626 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 72 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1995 | 618 | 0.030 |
Why?
|
| Tablets | 1 | 2013 | 19 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 246 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 1993 | 955 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 1994 | 107 | 0.030 |
Why?
|
| Home Care Services | 1 | 1994 | 84 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 56 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 2013 | 57 | 0.030 |
Why?
|
| Age of Onset | 3 | 1999 | 188 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 35 | 0.030 |
Why?
|
| Sex Characteristics | 3 | 2000 | 295 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1993 | 40 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 413 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2013 | 67 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 59 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1993 | 59 | 0.030 |
Why?
|
| Tretinoin | 1 | 2013 | 92 | 0.030 |
Why?
|
| Victoria | 1 | 2012 | 8 | 0.030 |
Why?
|
| Minocycline | 1 | 2013 | 61 | 0.030 |
Why?
|
| Hospitals, Private | 1 | 2012 | 15 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2012 | 22 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 1993 | 86 | 0.030 |
Why?
|
| Second Messenger Systems | 2 | 1991 | 53 | 0.030 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2012 | 3 | 0.030 |
Why?
|
| Attitude to Health | 2 | 2009 | 403 | 0.030 |
Why?
|
| Moricizine | 1 | 1992 | 1 | 0.030 |
Why?
|
| Defense Mechanisms | 1 | 1972 | 14 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1994 | 268 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2017 | 657 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2013 | 328 | 0.030 |
Why?
|
| Drug Overdose | 1 | 1992 | 67 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 199 | 0.020 |
Why?
|
| Lymphokines | 1 | 1991 | 49 | 0.020 |
Why?
|
| Uncertainty | 1 | 2011 | 31 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 1993 | 183 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 149 | 0.020 |
Why?
|
| Self Concept | 1 | 1972 | 132 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 190 | 0.020 |
Why?
|
| Rest | 1 | 2011 | 78 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 2011 | 8 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2011 | 13 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1991 | 50 | 0.020 |
Why?
|
| Magnesium | 1 | 1991 | 110 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2011 | 69 | 0.020 |
Why?
|
| Health Expenditures | 1 | 1993 | 170 | 0.020 |
Why?
|
| Erythema | 1 | 1991 | 18 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Juvenile Delinquency | 1 | 1972 | 129 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 35 | 0.020 |
Why?
|
| Rural Health | 1 | 1991 | 66 | 0.020 |
Why?
|
| Health Policy | 1 | 1993 | 221 | 0.020 |
Why?
|
| Potassium | 1 | 1991 | 168 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 81 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 47 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 329 | 0.020 |
Why?
|
| Chest Pain | 1 | 1991 | 151 | 0.020 |
Why?
|
| Protein Structure, Secondary | 2 | 2001 | 136 | 0.020 |
Why?
|
| Anesthesiology | 1 | 2011 | 63 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 30 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2010 | 85 | 0.020 |
Why?
|
| Hypotension | 1 | 1991 | 74 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 1990 | 62 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2000 | 189 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2010 | 133 | 0.020 |
Why?
|
| Value of Life | 2 | 2000 | 14 | 0.020 |
Why?
|
| Urticaria | 1 | 1991 | 84 | 0.020 |
Why?
|
| Health Promotion | 1 | 1994 | 407 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 1990 | 35 | 0.020 |
Why?
|
| Cardiac Volume | 1 | 2009 | 21 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 241 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 329 | 0.020 |
Why?
|
| Cholesterol | 1 | 1991 | 331 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2009 | 10 | 0.020 |
Why?
|
| Pain Clinics | 1 | 2009 | 8 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 711 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2009 | 33 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2009 | 65 | 0.020 |
Why?
|
| Cough | 1 | 1990 | 65 | 0.020 |
Why?
|
| Eggs | 1 | 1989 | 21 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2009 | 45 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 128 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2009 | 137 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1989 | 22 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 507 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1989 | 71 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 160 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 453 | 0.020 |
Why?
|
| Mass Screening | 2 | 1993 | 843 | 0.020 |
Why?
|
| Penicillin G | 2 | 2000 | 8 | 0.020 |
Why?
|
| Feedback | 1 | 1989 | 90 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 246 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 322 | 0.020 |
Why?
|
| Haplotypes | 2 | 1999 | 174 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2009 | 156 | 0.020 |
Why?
|
| Hydrogen Bonding | 2 | 2000 | 67 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 1993 | 866 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1987 | 35 | 0.020 |
Why?
|
| Thionucleotides | 1 | 1987 | 21 | 0.020 |
Why?
|
| Florida | 2 | 2000 | 221 | 0.020 |
Why?
|
| Drug Design | 2 | 2000 | 107 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2009 | 369 | 0.020 |
Why?
|
| Fluticasone | 2 | 1998 | 12 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 186 | 0.020 |
Why?
|
| Health Surveys | 3 | 1996 | 489 | 0.020 |
Why?
|
| Primary Health Care | 1 | 1993 | 703 | 0.020 |
Why?
|
| Policy Making | 1 | 2007 | 51 | 0.020 |
Why?
|
| Baroreflex | 1 | 2007 | 20 | 0.020 |
Why?
|
| Phosphatidic Acids | 1 | 1987 | 12 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2010 | 384 | 0.020 |
Why?
|
| Hydrolysis | 1 | 1987 | 144 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 689 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 448 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2001 | 502 | 0.020 |
Why?
|
| Food Industry | 1 | 2004 | 7 | 0.020 |
Why?
|
| Behavior | 1 | 2005 | 59 | 0.020 |
Why?
|
| Seasons | 1 | 2004 | 129 | 0.010 |
Why?
|
| Mediastinal Cyst | 1 | 1984 | 5 | 0.010 |
Why?
|
| Pancreatic Pseudocyst | 1 | 1984 | 24 | 0.010 |
Why?
|
| Pancreatic Cyst | 1 | 1984 | 16 | 0.010 |
Why?
|
| Pancreatic Fistula | 1 | 1984 | 23 | 0.010 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 2003 | 7 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2550 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 111 | 0.010 |
Why?
|
| Schools | 1 | 2004 | 156 | 0.010 |
Why?
|
| Lymphangioma | 1 | 1983 | 2 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 92 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2009 | 824 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 782 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2002 | 20 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 67 | 0.010 |
Why?
|
| Columbidae | 1 | 1981 | 12 | 0.010 |
Why?
|
| Visual Pathways | 1 | 1981 | 31 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2001 | 31 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2001 | 64 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2001 | 129 | 0.010 |
Why?
|
| Solutions | 1 | 2001 | 115 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 165 | 0.010 |
Why?
|
| Drug Implants | 1 | 2000 | 19 | 0.010 |
Why?
|
| Lead | 1 | 2001 | 45 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2001 | 125 | 0.010 |
Why?
|
| Light | 1 | 1981 | 152 | 0.010 |
Why?
|
| Sensory Thresholds | 1 | 2000 | 50 | 0.010 |
Why?
|
| Mental Health | 1 | 2003 | 278 | 0.010 |
Why?
|
| Prejudice | 1 | 2000 | 37 | 0.010 |
Why?
|
| Codon | 1 | 2000 | 21 | 0.010 |
Why?
|
| Acylation | 1 | 2000 | 22 | 0.010 |
Why?
|
| Virulence | 1 | 2000 | 51 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2000 | 15 | 0.010 |
Why?
|
| Peer Group | 1 | 2001 | 104 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1999 | 16 | 0.010 |
Why?
|
| Prothrombin | 1 | 1999 | 12 | 0.010 |
Why?
|
| Cations | 1 | 1999 | 51 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1999 | 44 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 70 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2000 | 190 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 188 | 0.010 |
Why?
|
| Dizziness | 1 | 1999 | 27 | 0.010 |
Why?
|
| Disabled Persons | 1 | 2000 | 94 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1999 | 58 | 0.010 |
Why?
|
| Developed Countries | 1 | 1999 | 8 | 0.010 |
Why?
|
| Epinephrine | 1 | 1999 | 103 | 0.010 |
Why?
|
| Ethical Theory | 1 | 1999 | 4 | 0.010 |
Why?
|
| Electrodiagnosis | 1 | 1999 | 12 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 1999 | 91 | 0.010 |
Why?
|
| Wakefulness | 1 | 1999 | 75 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1999 | 215 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1999 | 106 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2000 | 241 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1999 | 226 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2000 | 102 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1999 | 276 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2000 | 320 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2000 | 346 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1999 | 86 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1999 | 235 | 0.010 |
Why?
|
| Pancreas | 1 | 1999 | 225 | 0.010 |
Why?
|
| Community Health Centers | 1 | 1998 | 26 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 1998 | 10 | 0.010 |
Why?
|
| Hemolysin Proteins | 1 | 1998 | 9 | 0.010 |
Why?
|
| Genistein | 1 | 1998 | 26 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1999 | 330 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1999 | 213 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 69 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2000 | 498 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1998 | 237 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1998 | 187 | 0.010 |
Why?
|
| Flavonoids | 1 | 1998 | 109 | 0.010 |
Why?
|
| Presenilin-1 | 1 | 1997 | 28 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 16 | 0.010 |
Why?
|
| Homozygote | 1 | 1997 | 119 | 0.010 |
Why?
|
| Federal Government | 1 | 1996 | 13 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1999 | 296 | 0.010 |
Why?
|
| Crystallography | 1 | 1996 | 8 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2000 | 514 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 1996 | 13 | 0.010 |
Why?
|
| Pharyngitis | 1 | 1996 | 10 | 0.010 |
Why?
|
| Pulmonary Ventilation | 1 | 1996 | 28 | 0.010 |
Why?
|
| Nose | 1 | 1996 | 36 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 88 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 302 | 0.010 |
Why?
|
| Headache | 1 | 1996 | 68 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 357 | 0.010 |
Why?
|
| Income | 1 | 1996 | 167 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1998 | 431 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1996 | 155 | 0.010 |
Why?
|
| Streptomyces lividans | 1 | 1994 | 1 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 282 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 1995 | 179 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 303 | 0.010 |
Why?
|
| Continental Population Groups | 1 | 1993 | 1 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1994 | 48 | 0.010 |
Why?
|
| Geriatrics | 1 | 1994 | 69 | 0.010 |
Why?
|
| Nurse Practitioners | 1 | 1994 | 90 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 35 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1995 | 323 | 0.010 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1992 | 14 | 0.010 |
Why?
|
| Achievement | 1 | 1972 | 22 | 0.010 |
Why?
|
| Role | 1 | 1972 | 25 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 85 | 0.010 |
Why?
|
| Consciousness | 1 | 1972 | 17 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 245 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1992 | 234 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1992 | 47 | 0.010 |
Why?
|
| Psychology, Adolescent | 1 | 1972 | 38 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1994 | 954 | 0.010 |
Why?
|
| Hypokalemia | 1 | 1991 | 12 | 0.010 |
Why?
|
| Parent-Child Relations | 1 | 1972 | 98 | 0.010 |
Why?
|
| Rifabutin | 1 | 1991 | 5 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 1991 | 7 | 0.010 |
Why?
|
| Lipid A | 1 | 1991 | 9 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1991 | 25 | 0.010 |
Why?
|
| Quinones | 1 | 1991 | 13 | 0.010 |
Why?
|
| Benzoquinones | 1 | 1991 | 13 | 0.010 |
Why?
|
| Minority Groups | 1 | 1993 | 197 | 0.010 |
Why?
|
| Salmonella | 1 | 1991 | 20 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1991 | 100 | 0.010 |
Why?
|
| Diuretics | 1 | 1991 | 97 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1991 | 134 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 492 | 0.010 |
Why?
|
| Body Image | 1 | 1972 | 100 | 0.010 |
Why?
|
| Social Behavior | 1 | 1972 | 164 | 0.010 |
Why?
|
| Nitrogen | 1 | 1971 | 57 | 0.010 |
Why?
|
| Medicaid | 1 | 1993 | 302 | 0.010 |
Why?
|
| Glycosylation | 1 | 1991 | 185 | 0.010 |
Why?
|
| Intradermal Tests | 1 | 1990 | 3 | 0.010 |
Why?
|
| Avoidance Learning | 1 | 1971 | 58 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1971 | 173 | 0.010 |
Why?
|
| Ontario | 1 | 1990 | 24 | 0.010 |
Why?
|
| RNA | 1 | 1971 | 171 | 0.010 |
Why?
|
| Students | 1 | 1972 | 233 | 0.010 |
Why?
|
| Emergencies | 1 | 1990 | 107 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1971 | 290 | 0.010 |
Why?
|
| Anxiety | 1 | 1972 | 422 | 0.010 |
Why?
|
| Digestive System | 1 | 1968 | 35 | 0.000 |
Why?
|
| Motivation | 1 | 1972 | 561 | 0.000 |
Why?
|
| Internship and Residency | 1 | 1993 | 596 | 0.000 |
Why?
|
| Polymyxin B | 1 | 1986 | 5 | 0.000 |
Why?
|
| Peptidoglycan | 1 | 1986 | 14 | 0.000 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1986 | 31 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1986 | 63 | 0.000 |
Why?
|
| Immune Tolerance | 1 | 1986 | 114 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1968 | 299 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1986 | 312 | 0.000 |
Why?
|
| Aging | 1 | 1971 | 911 | 0.000 |
Why?
|
| Pancreatic Ducts | 1 | 1984 | 76 | 0.000 |
Why?
|
| Lymphography | 1 | 1983 | 3 | 0.000 |
Why?
|
| Pancreatitis | 1 | 1984 | 279 | 0.000 |
Why?
|
| Contrast Media | 1 | 1983 | 595 | 0.000 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1968 | 13 | 0.000 |
Why?
|
| Agglutination Tests | 1 | 1968 | 9 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1968 | 65 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1968 | 141 | 0.000 |
Why?
|